Table 3. Comparison of the diagnostic test between SLN-CEUS and BUS.
| Metric | Overall patients | Non-NAT patients | NAT patients | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SLN-CEUS | BUS | P value* | SLN-CEUS | BUS | P value* | SLN-CEUS | BUS | P value* | |||
| Sensitivity | 69.7% (53/76); (95% CI, 58.0–79.5%) | 59.3% (54/91); (95% CI, 48.5–69.4%) | 0.218 | 76.9% (30/39); (95% CI, 60.3–88.3%) | 51.9% (27/52); (95% CI, 37.8–65.8%) | 0.026 | 62.2% (23/37); (95% CI, 44.8–77.1%) | 69.2% (27/39); (95% CI, 52.3–82.5%) | 0.910 | ||
| Specificity | 84.1% (211/251); (95% CI, 78.8–88.2%) | 79.2% (187/236); (95% CI, 73.4–84.1%) | 0.208 | 89.9% (161/179); (95% CI, 84.3–93.8%) | 83.1% (147/177); (95% CI, 76.5–88.1%) | 0.080 | 69.4% (50/72); (95% CI, 57.3–79.5%) | 67.8% (40/59); (95% CI, 54.2–79.0%) | >0.99 | ||
| PPV | 57.0% (53/93); (95% CI, 46.3–67.1%) | 52.4% (54/103); (95% CI, 42.4–62.3%) | 0.619 | 62.5% (30/48); (95% CI, 47.3–75.7%) | 47.4% (27/57); (95% CI, 34.2–60.9%) | 0.176 | 51.1% (23/45); (95% CI, 36.0–66.1%) | 58.7% (27/46); (95% CI, 43.3–72.7%) | 0.606 | ||
| NPV | 90.2% (211/234); (95% CI, 85.4–93.5%) | 83.5% (187/224); (95% CI, 77.8–88.0%) | 0.048 | 94.7% (161/170); (95% CI, 89.9–97.4%) | 85.5% (147/172); (95% CI, 79.1–90.2%) | 0.007 | 78.1% (50/64); (95% CI, 65.7–87.1%) | 76.9% (40/52); (95% CI, 62.8–87.0%) | >0.99 | ||
| FNR | 30.3% (23/76); (95% CI, 20.5–42.0%) | 40.7% (37/91); (95% CI, 30.6–51.5%) | 0.218 | 23.1% (9/39); (95% CI, 11.7–39.7%) | 48.1% (25/52); (95% CI, 34.2–62.2%) | 0.026 | 37.8% (14/37); (95% CI, 22.9–55.2%) | 30.8% (12/39); (95% CI, 17.5–47.7%) | 0.684 | ||
| FPR | 15.9% (40/251); (95% CI, 11.8–21.2%) | 20.8% (49/236); (95% CI, 15.9–26.6%) | 0.208 | 10.1% (18/179); (95% CI, 6.2–15.7%) | 16.9% (30/177); (95% CI, 11.9–23.5%) | 0.080 | 30.6% (22/72); (95% CI, 20.5–42.7%) | 32.2% (19/59); (95% CI, 21.0–45.8%) | 0.990 | ||
| Accuracy | 80.7% (264/327); (95% CI, 76.5–85.0%) | 73.7% (241/327); (95% CI, 68.9–78.5%) | <0.001 | 87.6% (191/218); (95% CI, 83.2–92.0%) | 76.0% (174/229); (95% CI, 70.4–81.5%) | <0.001 | 67.0% (73/109); (95% CI, 58.1–75.8%) | 68.4% (67/98); (95% CI, 59.2–77.6%) | 0.948 | ||
*, P values are from the chi-square test or Fisher exact test, as appropriate. SLN-CEUS, contrast-enhanced ultrasound of sentinel lymph node; BUS, B-mode ultrasound; PPV, positive predictive value; NPV, negative predictive value; FNR, false negative rate; FPR, false positive rate.